News
TVTX
17.57
+0.40%
0.07
Travere Therapeutics Is Maintained at Sector Outperform by Scotiabank
Dow Jones · 12h ago
Scotiabank Maintains Sector Outperform on Travere Therapeutics, Raises Price Target to $27
Benzinga · 12h ago
Travere Therapeutics Is Maintained at Overweight by Barclays
Dow Jones · 12h ago
Barclays Maintains Overweight on Travere Therapeutics, Raises Price Target to $20
Benzinga · 13h ago
Travere Therapeutics (TVTX) Gets a Buy from Bank of America Securities
TipRanks · 13h ago
Travere Therapeutics price target raised to $27 from $23 at Scotiabank
TipRanks · 14h ago
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Takeda Pharmaceutical Company (TAK) and Voyager Therapeutics (VYGR)
TipRanks · 15h ago
Travere Therapeutics: Strong Growth and Strategic Advancements Drive Buy Rating
TipRanks · 16h ago
Travere Therapeutics price target raised to $20 from $18 at Barclays
TipRanks · 17h ago
Travere Therapeutics (TVTX) Receives a Buy from Barclays
TipRanks · 19h ago
Travere Therapeutics Boosts Sales with FILSPARI Approval
TipRanks · 22h ago
TRAVERE THERAPEUTICS: ENTERED AMENDED & RESTATED AGREEMENT OF UPTO $100 MLN IN COMMON STOCK OFFERING
Reuters · 1d ago
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 1d ago
Travere Therapeutics beats Q3 revenue estimates
Seeking Alpha · 1d ago
Travere Therapeutics Q3 2024 GAAP EPS $(0.70), Inline, Sales $62.90M Beat $59.70M Estimate
Benzinga · 1d ago
*Travere Therapeutics 3Q Loss/Shr 70c >TVTX
Dow Jones · 1d ago
A Preview Of Travere Therapeutics's Earnings
Benzinga · 2d ago
Travere Therapeutics Q3 2024 Earnings Preview
Seeking Alpha · 2d ago
U.S. RESEARCH ROUNDUP-Agilon Health, Alphabet, Crocs
Reuters · 2d ago
TRAVERE THERAPEUTICS INC <TVTX.O>: JEFFERIES RAISES TARGET PRICE TO $33 FROM $17
Reuters · 2d ago
More
Webull provides a variety of real-time TVTX stock news. You can receive the latest news about Travere Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).